Jump to ContentJump to Main Navigation
Show Summary Details

Open Medicine

formerly Central European Journal of Medicine

IMPACT FACTOR increased in 2015: 0.190
5-year IMPACT FACTOR: 0.221

SCImago Journal Rank (SJR) 2015: 0.140
Source Normalized Impact per Paper (SNIP) 2015: 0.154
Impact per Publication (IPP) 2015: 0.197

Open Access
See all formats and pricing

Select Volume and Issue
Loading journal volume and issue information...

Malignancies after kidney transplantation: 3 clinical case reports

1132Department of Nephrology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania

2132Department of Onco-haematology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania

3132Department of Urology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania

© 2013 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. (CC BY-NC-ND 3.0)

Citation Information: Open Medicine. Volume 8, Issue 3, Pages 322–327, ISSN (Online) 2391-5463, DOI: 10.2478/s11536-012-0132-7, April 2013

Publication History

Published Online:


Post-transplant malignancies present an aggressive course and are a significant cause of morbidity and mortality. Tumours of viral ethiology have the greatest risk in renal transplant recipients. Oncogenic effect of immunosuppressive therapy is another major risk factor of post-transplant malignancy. We report cases of three different types of malignancies developed after kidney transplantation: non-Hodgkin’s lymphoma, Kaposi’s sarcoma and germ cell testicular cancer (nonseminoma).

Keywords: Kidney transplantation; Malignancy; Non-Hodgkin’s lymphoma; Kaposi’s sarcoma; Germ cell testicular cancer (nonseminoma)

  • [1] Sheil AG, Disney APS, Mathew TH, et al. De novo malignancy emerges as a major causes of morbidity and late failure in renal transplantation. Transplant Proc 1993;25:1383 [PubMed]

  • [2] Peto J. Cancer epidemiology in the last century and the next decade. Nature 2001;411:390–395 http://dx.doi.org/10.1038/35077256 [CrossRef]

  • [3] Birkeland SA, Lokkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation. Lancet 2000;355:1886–1887 http://dx.doi.org/10.1016/S0140-6736(00)02298-4 [CrossRef]

  • [4] Zeier M, Hartschuh W, Wiesel M, Lehnert T, Ritz E. Malignancy after renal transplantation. Am J Kidney Dis 2002;39:E5 http://dx.doi.org/10.1053/ajkd.2002.29926 [CrossRef]

  • [5] Wimmer CD, Rentsch M, Crispin A, et al. The janus face of immunosuppression — de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int. 2007;71:1271–1278 http://dx.doi.org/10.1038/sj.ki.5002154 [CrossRef]

  • [6] Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am. J. Transplant. 2004;4:905–913 http://dx.doi.org/10.1111/j.1600-6143.2004.00450.x [CrossRef]

  • [7] Morath C, Mueller M, Goldschmidt H et al. Malignancy in renal transplantation. J Am Soc Nephrol 2004;15:1582–1588 http://dx.doi.org/10.1097/01.ASN.0000126194.77004.9B [CrossRef]

  • [8] Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for endstage renal disease: an international collaborative study. Lancet 1999;354:93–99 http://dx.doi.org/10.1016/S0140-6736(99)06154-1 [CrossRef]

  • [9] Briggs JD. Causes of death after renal transplantation. Nephrol. Dial. Transplant. 2001;16:1545–154 http://dx.doi.org/10.1093/ndt/16.8.1545 [CrossRef]

  • [10] Yang TC, Shu KH, Cheng CH, Wu MJ, Lian JD. Malignancy following renal transplantation. Zhonghua Yi Xue Za Zhi (Taipei) 1998;61:281–288

  • [11] Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002;73:1923–1928 http://dx.doi.org/10.1097/00007890-200206270-00013 [CrossRef]

  • [12] Collins AJ, et al. Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2003;42(5):S1–S230

  • [13] Miao Y, Everly JJ, Gross TG, Tevar AD et al. De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation 2009;87:1347–1359 http://dx.doi.org/10.1097/TP.0b013e3181a238f6 [CrossRef]

  • [14] Kauffman HM, Cherikh WS, McBride MA et al. Posttransplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int 2006; 19:607–620 http://dx.doi.org/10.1111/j.1432-2277.2006.00330.x [CrossRef]

  • [15] Caillard S, Dharnidharka V, Agodoa L et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80:1233–1243 http://dx.doi.org/10.1097/01.tp.0000179639.98338.39 [CrossRef]

  • [16] Liebowitz, D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med. 1998; 338:1413–1421 http://dx.doi.org/10.1056/NEJM199805143382003 [CrossRef]

  • [17] Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4:222–230 http://dx.doi.org/10.1046/j.1600-6143.2003.00325.x [CrossRef]

  • [18] Dantal J, Hourmant M, Cantorovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomized comparison of two cyclosporin regimens. Lancet 1998;351:623–628 http://dx.doi.org/10.1016/S0140-6736(97)08496-1 [CrossRef]

  • [19] Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant. 2007;7:2619–2625 http://dx.doi.org/10.1111/j.1600-6143.2007.01972.x [CrossRef]

  • [20] Schmidtko J, Wang R, Wu CL, et al. Posttransplant lymphoproliferative disorder associated with an Epstein-Barr-related virus in cynomolgus monkeys. Transplantation 2002;73:1431–1439 http://dx.doi.org/10.1097/00007890-200205150-00012 [CrossRef]

  • [21] Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342:1514–1516 http://dx.doi.org/10.1016/S0140-6736(05)80084-4 [CrossRef]

  • [22] Campistol JM, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006;1:581–589 http://dx.doi.org/10.1681/ASN.2005090993 [CrossRef]

  • [23] Kahan BD, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005;80:749–758 http://dx.doi.org/10.1097/01.TP.0000173770.42403.F7 [CrossRef]

  • [24] Chapman JR, Capistol JM. Malignancy in renal transplantation: opportunities with proliferation signal inhibitors. Nephrol Dial Transplant 2007;22 (l):i1–i3 http://dx.doi.org/10.1093/ndt/gfm087 [CrossRef]

  • [25] Gurk-Turner C, Manitpisitkul W, Cooper M. A comprehensive review of everolimus clinical reports: a new Mammalian target of rapamycin inhibitor. Transplantation. 2012;94(7):659–68 http://dx.doi.org/10.1097/TP.0b013e31825b411c [CrossRef]

  • [26] Kasiske BL, Kukla A, Thomas D, et al. Lymphoproliferative Disorders After Adult Kidney Transplant: Epidemiology and Comparison of Registry Report With Claims-Based Diagnoses. Am J Kidney Dis 2011;58(6):971–980 http://dx.doi.org/10.1053/j.ajkd.2011.07.015 [Web of Science] [CrossRef]

  • [27] Gotti E, Remuzzi G: Post-transplant Kaposi’s sarcoma. J Am Soc Nephrol 1997;8:130–137 [PubMed]

  • [28] Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi’s sarcoma. Transplantation 2004;77:760–762 http://dx.doi.org/10.1097/01.TP.0000115344.18025.0B [CrossRef]

  • [29] Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 2005;352:1317–1323 http://dx.doi.org/10.1056/NEJMoa042831 [CrossRef]

  • [30] Shepherd FA, Maher E, Cardella C, et al. Treatment of Kaposi’s sarcoma after solid organ transplantation. J Clin Oncol 1997;15:2371–2377

  • [31] Brambilla L, Labianca R, Boneschi V, et al. Mediterranean Kaposi’s sarcoma in the elderly: a randomized study of oral etoposide versus vinblastine. Cancer 1994;74:2873–2878 http://dx.doi.org/10.1002/1097-0142(19941115)74:10<2873::AID-CNCR2820741021>3.0.CO;2-1 [CrossRef]

  • [32] Olay Dahl, Geirfinn Vagstad, Bjarne Iversen. Cisplatin-based chemotherapy in a renal transplant recipient with metastatic germ cell testicular cancer. Acta Oncologica 1996; 35:759–761 http://dx.doi.org/10.3109/02841869609084013 [CrossRef]

  • [33] Dean C, Bloomfield D, Holt S. The challenge of germ cell tumour therapy in dialysis and transplantation. Nephrol Dial Transplant. 2005;20(12):2867–2868 http://dx.doi.org/10.1093/ndt/gfi108 [CrossRef]

  • [34] Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, et al. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol. 2000;11:S1–86 [PubMed]

  • [35] European Best Practice Guidelines. Nephrol Dial Transplant 2002;17(4):37

  • [36] Penn I. Transmission of cancer from organ donor. Nefrologia 1995;15(3):205–213

  • [37] Kauffman HM, McBride MA, Delmonico FL. First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation. 2000;70(12):1747–1751 http://dx.doi.org/10.1097/00007890-200012270-00014 [CrossRef]

  • [38] Garrido G, Matesanz R. The Spanish National Transplant Organization (ONT) tumor registry. Transplantation 2008;85(8):S61–63 http://dx.doi.org/10.1097/TP.0b013e31816c2f55 [CrossRef]

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Reactions Weekly, 2013, Volume 1457, Number 1, Page 23

Comments (0)

Please log in or register to comment.